Literature DB >> 6413596

Effect of erythromycin on microbial antagonisms: a study in gnotobiotic mice associated with a human fecal flora.

A Andremont, P Raibaud, C Tancrède.   

Abstract

The effect of erythromycin base was studied on intestinal resistance to colonization of gnotobiotic mice inoculated with a human fecal flora and challenged with six microbial strains potentially pathogenic for immunocompromised patients. Fecal concentrations of erythromycin were greater than 1,000 micrograms/g in the human donor and in mice. Total intestinal bacterial counts were not significantly different in the human donor and in the recipient mice and were not affected by erythromycin treatment. Strains of various species from the dominant flora (greater than 10(9) colony-forming units/g) and resistant to greater than 1,000 micrograms of erythromycin/ml were present before and persisted during treatment. Strains sensitive to such concentrations - particularly all enterobacteria-were eliminated. Treatment did not reduce colonization resistance against Candida albicans, Clostridium perfringens, and erythromycin-sensitive Escherichia coli. It reduced but did not eliminate some colonization resistance against Pseudomonas aeruginosa, Clostridium difficile, and erythromycin-resistant E coli.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6413596     DOI: 10.1093/infdis/148.3.579

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

1.  Effects of roxithromycin on fecal bacteria in human volunteers and resistance to colonization in gnotobiotic mice.

Authors:  S Pecquet; E Chachaty; C Tancrède; A Andremont
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  Inducible transfer of conjugative transposon Tn1545 from Enterococcus faecalis to Listeria monocytogenes in the digestive tracts of gnotobiotic mice.

Authors:  F Doucet-Populaire; P Trieu-Cuot; I Dosbaa; A Andremont; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

3.  Application of nanoscale packed capillary liquid chromatography (75 μm id) and capillary zone electrophoresis/electrospray ionization mass spectrometry to the analysis of macrolide antibiotics.

Authors:  C E Parker; J R Perkins; K B Tomer; Y Shida; K O'Hara; M Kono
Journal:  J Am Soc Mass Spectrom       Date:  1992-07       Impact factor: 3.109

Review 4.  Rodent models to study the relationships between mammals and their bacterial inhabitants.

Authors:  Rodrigo Bibiloni
Journal:  Gut Microbes       Date:  2012-08-23

5.  Purification and characterization of macrolide 2'-phosphotransferase from a strain of Escherichia coli that is highly resistant to erythromycin.

Authors:  K O'Hara; T Kanda; K Ohmiya; T Ebisu; M Kono
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

6.  Individual evolution of digestive tract colonization of holoxenic mice by Candida albicans.

Authors:  S Walbaum; L Dujardin
Journal:  Infect Immun       Date:  1985-05       Impact factor: 3.441

7.  Ecology of Candida albicans gut colonization: inhibition of Candida adhesion, colonization, and dissemination from the gastrointestinal tract by bacterial antagonism.

Authors:  M J Kennedy; P A Volz
Journal:  Infect Immun       Date:  1985-09       Impact factor: 3.441

8.  Plasmid-mediated susceptibility to intestinal microbial antagonisms in Escherichia coli.

Authors:  A Andremont; G Gerbaud; C Tancrède; P Courvalin
Journal:  Infect Immun       Date:  1985-09       Impact factor: 3.441

9.  In vitro activity of azithromycin against bacterial enteric pathogens.

Authors:  M E Gordillo; K V Singh; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

10.  Reaction of roxithromycin and clarithromycin with macrolide-inactivating enzymes from highly erythromycin-resistant Escherichia coli.

Authors:  K O'Hara; K Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.